Investor Relations (IR) Questions: NewLink Genetics Corporation NLNK
Click here to return to the biotech IRQ Index
Answers received: March 2013
1) When is the last time NLNK raised cash through an offering (diluted)?
IPO was 11/11/2011; last round was 2/4/2013 (no stock sales in between)
2) How much cash (not cash equivalents) does NLNK have?
NLNK does not disclose cash separately from Cash equivalents. We have not yet filed our 10-K, but we disclosed “cash, cash equivalents and certificates of deposit” totaled $21,744,000 at December 31, 2012 and we disclosed that net proceeds from the financing that closed in early February were $49.o million.
3) What and approximately when is the next known catalyst?
Obviously, “catalyst” is in the eyes of the beholder. Here are some near term events that may be catalysts; we will be presenting data for some of our studies at ASCO in June; we have disclosed that completion of patient enrollment in our phase 3 IMPRESS study is expect this summer; and, we disclosed that we hope to complete the first interim analysis of patient data for our phase 3 IMPRESS study will occur around mid-year.
4) What is NLNK's quarterly cash burn?
Although we don’t specifically provide quarterly spending data, we have guided the strett to an expected year end balance of “about $40 million in cash, cash equivalents and marketable securities.”
5) Does NLNK have an existing line of credit and if so how much can they draw against it?
We do not have an “existing line of credit “
Best regards,
Gordon Link
Chief Financial Officer
NewLink Genetics Corporation
1) When is the last time NLNK raised cash through an offering (diluted)?
IPO was 11/11/2011; last round was 2/4/2013 (no stock sales in between)
2) How much cash (not cash equivalents) does NLNK have?
NLNK does not disclose cash separately from Cash equivalents. We have not yet filed our 10-K, but we disclosed “cash, cash equivalents and certificates of deposit” totaled $21,744,000 at December 31, 2012 and we disclosed that net proceeds from the financing that closed in early February were $49.o million.
3) What and approximately when is the next known catalyst?
Obviously, “catalyst” is in the eyes of the beholder. Here are some near term events that may be catalysts; we will be presenting data for some of our studies at ASCO in June; we have disclosed that completion of patient enrollment in our phase 3 IMPRESS study is expect this summer; and, we disclosed that we hope to complete the first interim analysis of patient data for our phase 3 IMPRESS study will occur around mid-year.
4) What is NLNK's quarterly cash burn?
Although we don’t specifically provide quarterly spending data, we have guided the strett to an expected year end balance of “about $40 million in cash, cash equivalents and marketable securities.”
5) Does NLNK have an existing line of credit and if so how much can they draw against it?
We do not have an “existing line of credit “
Best regards,
Gordon Link
Chief Financial Officer
NewLink Genetics Corporation